NCT05943990 - Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions

Neoplasms

Interventions

DRUG

GSK3845097

GSK3845097 was administered.

DRUG

Cyclophosphamide

Cyclophosphamide was administered as lymphodepleting chemotherapy.

DRUG

Fludarabine

Fludarabine was administered as lymphodepleting chemotherapy.

Trial Locations (21)

3000

GSK Investigational Site, Melbourne

10032

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

19111

GSK Investigational Site, Philadelphia

21287

GSK Investigational Site, Baltimore

30322

GSK Investigational Site, Atlanta

30625

GSK Investigational Site, Hanover

32224

GSK Investigational Site, Jacksonville

33612

GSK Investigational Site, Tampa

40536

GSK Investigational Site, Lexington

50937

GSK Investigational Site, Cologne

63110

GSK Investigational Site, St Louis

66205

GSK Investigational Site, Westwood

77030

GSK Investigational Site, Houston

81377

GSK Investigational Site, Munich

06504

GSK Investigational Site, New Haven

M5G 2M9

GSK Investigational Site, Toronto

H1T 2M4

GSK Investigational Site, Montreal

01307

GSK Investigational Site, Dresden

1066 CX

GSK Investigational Site, Amsterdam

SE-171 64

GSK Investigational Site, Stockholm